levodopa/carbidopa (ND0680) / Mitsubishi Tanabe - LARVOL DELTA

Effect of 24-hour subcutaneous levodopa/ carbidopa infusion (ND0612) on motor fluctuations in the Phase 3 BouNDless study (EAN 2025) - P3 | "These data confirm the effectiveness of the ND0612 regimen in reducing OFF, improving ON, and reducing the transitions between them, compared to IR-LD/CD."

P3 data • Movement Disorders

QUALITY OF LIFE WITH 24 -HOUR SUBCUTANEOUS LEVODOPA/CARBIDOPA INFUSION (ND0612): QOL RESULTS FROM A PHASE 3 RANDOMIZED, ACTIVE -CONTROLLED STUDY (ADPD 2025) - P3 | "ND0612 improved QoL compared to IR -LD/CD, further supporting the clinical meaningfulness of the observed reduction in motor fluctuations from the perspective of a patient with PD."

Clinical • HEOR • P3 data • CNS Disorders • Movement Disorders • Parkinson's Disease

ONE YEAR EFFICACY AND SAFETY OF ND0612 FOR MOTOR FLUCTUATIONS IN PARKINSON'S DISEASE: OPEN-LABEL EXTENSION PHASE OF THE BOUNDLESS STUDY (ADPD 2025) - "Aims: The double -blind phase of the BouNDless study demonstrated that treatment with investigational ND0612 provided patients with Parkinson's disease (PD) experiencing motor fluctuations an additional 1.72h of ON -time without troublesome dyskinesia (Good ON -time) compared with immediate -release levodopa/carbidopa (IR -LD/CD) (P<0.0001), with a favorable safety and tolerability profile... Results from this open -label extension phase confirm the 12 -month efficacy and safety of treatment with the ND0612 regimen in increasing Good ON -time and reducing OFF -time in patients with PD and motor fluctuations."

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Quality of Life with 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612): QoL Results from a Phase 3 Randomized, Active-controlled Study (AAN 2025) - P3 | "ND0612 improved QoL compared to IR-LD/CD, further supporting the clinical meaningfulness of the observed reduction in motor fluctuations from the perspective of a patient with PD."

Clinical • HEOR • P3 data • CNS Disorders • Movement Disorders • Parkinson's Disease

Impact of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612) on Motor Function: Efficacy Outcomes from the Phase 3 BouNDless Study (AAN 2025) - P3 | "Treatment with ND0612, versus IR-LD/CD, led to more stable motor control in patients with PD and motor fluctuations."

Clinical • P3 data • Movement Disorders

Long-term, continuous, subcutaneous levodopa/carbidopa infusion with ND0612 in Parkinson's disease: 3-year outcomes from the open-label BeyoND study. (PubMed, Parkinsonism Relat Disord) - P2 | "Three-year results from this open-label study support the long-term safety, tolerability, and efficacy of ND0612. For participants who entered the extension phase, the high rate of retention supports a favorable benefit-risk ratio of the ND0612 regimen for patients with PD experiencing motor fluctuations."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Enrollment characteristics for patients entering a phase 3 study of subcutaneous levodopa/carbidopa infusion with ND0612 (IAPRD 2023) - P3 | N=259 | BouNDless (NCT04006210) | Sponsor: NeuroDerm Ltd. | "Enrollment characteristics of patients randomized in the BouNDless trial are consistent with those observed in other clinical studies in PwP experiencing motor fluctuations."